Skip to main content
. 2021 May 25;21:602. doi: 10.1186/s12885-021-08291-9

Fig. 3.

Fig. 3

Subgroup analysis of progression-free survival HR: Hazard ratios; Del 19 del, exon 19 deletion; 21 L858R, exon 21 point mutation;T + C, EGFR-TKI combined with chemotherapy; T, EGFR-TKI monotherapy